nejm semaglutide cardiovascular For patients with #obesity, semaglutide, a glucagon-like peptide-1 receptor agonist, is approved for weight management as a once-weekly subcutaneous injection. In a previous trial, oral at a dose of 50 mg Semaglutide and Cardiovascular Outcomes in

These findings have led to increased interest in evaluating the therapeutic potential of VEGF as a neuroprotective agent in neurodegenerative diseases (Storkebaum and Carmeliet 2004)

Were talking about real results in human somatic cells

These include pancreatitis, vision problems like NAION or worsening diabetic retinopathy, low blood sugar when taken with insulin or sulfonylureas, acute kidney injury, severe digestive issues such as gastroparesis or ileus, allergic reactions, gallbladder disease and a higher risk of aspiration during surgery because Ozempic slows digestion

I can't see any blood test results for iron eg ferritin or any other iron tests